A new takeover offer for U.S. biotech firm Baxalta would create one of the world's leading specialists in rare diseases.» Read More
U.S. health regulators are seeking stronger warnings about the risk of pancreatitis after the deaths of two patients taking Amylin Pharmaceuticals' injectable diabetes drug Byetta, sending the company's shares down as much 16 percent.
Ads for flu vaccines have traditionally been confined to PSAs, health and media alerts. So that's why I was surprised to see this colorful full-page ad in The New York Times this weekend for FluMist from AstraZeneca/MedImmune. Why..?
Late last week I blogged that ImClone Systems founder and former CEO Sam Waksal was, according to a source, going to get out of a federal prison in Michigan and move into a halfway house in the Bronx between August 7th and the 14th.
This is how you balance Mad Money stock picks with your own portfolio.
This biotech sells its treatment to a niche clientele for big money.
Biotechnology company ImClone Systems, which rebuffed a $60-per-share takeover offer from Bristol-Myers Squibb, said on Thursday it hired JP Morgan Chase as its financialadviser.
The market cap of Dow component Johnson & Johnson is a whopping $200 billion. Abbott Labs is valued at less than half that. But think of ABT as kind of a mini-me JNJ because like Johnson & Johnson, ABT has cobbled together a similar three-siloed business of drugs, devices and consumer products.
Vertex Pharma is lagging its peers. But biotech is so good right now, it might not matter.
A new study and an editorial in a major medical journal could reignite the debate over whether drugs or stents or a combination of both are better for the millions of Americans with heart trouble.
Before I get to my favorite biotech saga, there are noteworthy, if not newsworthy, press releases out this morning from two takeout targets. Genentech put out a statement from the special independent board committee that's been appointed to handle the Roche buyout offer.
Genzyme may make orphan drugs, but this company is a lot closer to Daddy Warbucks.
For quite some time now the major American pharmaceutical companies have been benefitting from the foreign exchange rate. But given the recent strength in the greenback, Deutsche Bank analyst Barbara Ryan says the sector may not be able to rely on forex for very much longer.
Cramer offers up five reasons why this sector is the best one to own through the fall. Plus, the top stocks in the group.
I wanted to be sure and call attention to the fact that PFE is no longer a teenager. Shares of the Dow component have broken above $20. If the stock can stay there at 4 p.m. that'll be the first time Pfizer's closed above that level since May 21st.
Analysts are pretty much in agreement that Swiss drugmaker Roche is gonna have to pony up more than the 89 bucks it has already offered for the rest of Genentech it doesn't currently own.
Following are the week's biggest winners and losers, including a couple of well-known household goods companies, a luxury brand and a couple of techs thrown in for good measure.
The Elanians have been pretty quiet in the wake of last week's bad news. and the stock getting about a two-thirds haircut. And I don't mean to rub salt in the wound.
Following are Thursday's biggest winners and losers. Even with today's rough market, there were a number of pops, such as an internet florist, a Canadian fast food chain and a certain star athlete making the move to the Big Apple.
A week after Bristol-Myers Squibb made its move for ImClone Systems, one of the people who made the biotech infamous could be getting out of the clink.
In the latest move in the big pharma restructuring/outsourcing trend, Eli Lilly announced this morning that it's selling a lab site in its home state of Indiana to the contract research organization Covance.